HCTI's $50M AI Bet: Acquiring Spanish Firm to Reshape Global Healthcare

PLEASANTON, CA – January 22, 2026 – Healthcare Triangle, Inc. (Nasdaq: HCTI), a digital transformation firm for the life sciences sector, has announced a definitive agreement to acquire two Spanish AI firms in a deal valued at up to $50 million. The move is a bold gambit to pivot the company into a global leader in AI-powered patient engagement and dramatically reshape its financial future.

The acquisition targets Teyame 360 SL and Datono Mediacion SL, companies run by Teyame AI LLC, which are described as leaders in AI-powered omnichannel customer experience (CX) solutions. For Healthcare Triangle, this transaction is not just an expansion but a fundamental strategic overhaul, aiming to infuse advanced artificial intelligence into its core healthcare offerings while launching a major push into European and Latin American markets.

A High-Stakes Financial Transformation

This acquisition represents a monumental step for Healthcare Triangle, a company with a recent market capitalization hovering between $3 million and $6 million. The deal carries a total consideration of approximately $50 million, a figure that dwarfs HCTI's current market valuation. This price tag will be met through a complex mix of cash, shares of the company's common stock, shares of non-voting convertible preferred stock, and performance-based contingent earnouts, signaling a significant financial undertaking.

The company's leadership is betting that the acquisition will be transformative, projecting it will generate an incremental $38 million in revenue and $5 million in EBITDA over the next twelve months. These forecasts are aggressive, building upon the acquired assets' reported performance of approximately $32 million in revenue and $3.6 million in EBITDA for fiscal year 2025. For HCTI, which posted revenues of $12.9 million and a negative EBITDA of $5.9 million in its last twelve-month period, the influx of revenue and a shift to profitability would be a game-changer.

To support its growth ambitions, HCTI recently secured up to $15 million in financing through convertible promissory notes, a move that underscores its preparation for significant capital expenditure. The transaction is slated to close on January 29, 2026, pending shareholder approval and other standard conditions, but will be effective retroactively to January 1, 2026.

"The transaction will bring real world lived experience of Agentic Gen AI and is about to change the game for HCTI," said David Ayanoglou, Chief Financial Officer of HCTI, in the official announcement. "It's where the rubber meets the road in AI."

From Banking to Bedside: Teyame's Cross-Industry AI Prowess

At the heart of the deal are Teyame 360 SL and Datono Mediacion SL, two Madrid-based companies that have built a reputation outside of the healthcare industry. Their core expertise lies in developing sophisticated, AI-driven omnichannel customer experience (CX) platforms for demanding sectors like banking and insurance. Now, HCTI plans to redirect that proven technology toward the complexities of patient care.

Teyame's technology stack is built on what it calls "Agentic Generative AI," a system designed to deploy virtual AI teams tailored for specific business goals. This advanced platform supports everything from automated chatbots and multilingual engagement tools to real-time analytics. The company has already been piloting healthcare applications, but this acquisition marks a full-scale pivot into the sector.

The strategy involves a unique cross-pollination of technology. By taking a battle-tested AI engine from the finance and insurance worlds and integrating it with HCTI’s deep healthcare domain knowledge, the combined entity aims to leapfrog competitors. This approach seeks to solve long-standing challenges in patient communication and care coordination by applying AI models that have already proven their efficiency and scalability in other high-stakes, data-sensitive environments. The challenge, however, will be adapting these systems to the stringent regulatory and privacy requirements of healthcare, such as HIPAA in the United States and GDPR in Europe.

Crafting a Global Footprint in Healthcare AI

The acquisition is a cornerstone of HCTI's strategy to establish a significant international presence. Teyame's headquarters in Madrid provides an immediate and strategic springboard into the European and Latin American markets, which are identified as high-growth regions for digital healthcare solutions.

This move does not exist in a vacuum. It complements HCTI's ongoing expansion efforts in Asia through its wholly-owned subsidiary, QuantumNexis. The subsidiary's Ezovion Electronic Medical Record (EMR) platform is already being deployed in India, Bangladesh, Saudi Arabia, and Malaysia. By adding a strong European and Latin American presence, HCTI is assembling a global network for its SaaS offerings.

"Integrating these AI-powered engagement platforms with HCTI's healthcare technologies positions us to deliver a next-generation, intelligent ecosystem for patients, providers, and expanding SaaS Footprint into Europe and Latin America," stated Sujatha Ramesh, HCTI's Chief Operating Officer, Principal Executive Officer, and Director.

The goal is to create a unified global platform where AI-driven patient engagement is a core component. This would allow HCTI to offer a consistent, high-tech experience to healthcare systems, payers, and life sciences organizations across multiple continents, positioning it not just as a US-based IT provider but as a global force in the burgeoning healthcare AI market.

Weaving Intelligence into the Fabric of Patient Care

The ultimate vision behind the acquisition is to create an integrated ecosystem where every patient interaction is intelligent, personalized, and focused on improving health outcomes. This involves merging HCTI's established healthcare technology platforms, such as its HITRUST-certified CloudEz™ and DataEz™ platforms, with Teyame's advanced AI capabilities.

In practice, this could manifest in numerous ways. For patients, it might mean interacting with an AI-powered chatbot that can schedule appointments, provide pre-visit instructions, and answer questions in multiple languages, 24/7. For providers, it could mean leveraging real-time analytics to identify at-risk patients, automate follow-ups, and manage care plans more efficiently. The "AI-human collaboration models" touted by Teyame could allow administrative staff to offload repetitive tasks to AI agents, freeing them to focus on more complex patient needs.

By embedding Teyame's Agentic Gen AI into its core operations, HCTI aims to transform routine administrative touchpoints into opportunities for meaningful engagement. This shift from a reactive to a proactive model of patient communication is central to the company's strategy. The success of this integration will depend on the seamless fusion of Teyame's customer-centric AI with HCTI's clinical and data management expertise, a complex but potentially powerful combination. The transaction now awaits the crucial approval of HCTI's shareholders, which will determine if this ambitious vision for an AI-driven future in healthcare becomes a reality.